Weight Loss Ingredients

  • Christopher R. Mohr


Dietary supplements are and always will be immensely popular. Fat loss supplements are particularly popular as America is currently facing an obesity epidemic. Therefore, dietary supplements intended to enhance weight loss will continue to come and go over the years. Unfortunately, after reading this chapter, it should be apparent that few scientific data support many of the fat loss supplements available. The ephedra-containing supplements were effective for fat loss, but supplements with ephedra have been banned because it was surrounded by controversy as a result of some health concerns reported by consumers. Ironically, pure ephedrine can still be purchased.

Key Words

body mass obesity thermogenesis lipolysis appetite 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. TAMA 2002;288(14):1723–1727.Google Scholar
  2. 2.
    Kopelman PG. Obesity as a medical problem. Nature 2000:635–643.Google Scholar
  3. 3.
    Fugh-Berman A, Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp BioI Med (Maywood) 2004:698–704.Google Scholar
  4. 4.
    Colker CM, Kalman DS, Torina GC, Perlis T, Street C. Effects of Citrus aurantium extract, caffeine, and St. John’s wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr Ther Res 1999:145–153.Google Scholar
  5. 5.
    Pellati F, Benvenuti S, Melegari M, Firenzuoli F. Determination of adrenergic agonists from extracts and herbal products of Citrus aurantium L. var. amara by LC. J Pharm Biomed Anal 2002:1113–1119.Google Scholar
  6. 6.
    D’Andrea G, Terrazzino S, Fortin D, Farruggio A, Rinaldi L, Leon A, eds. HPLC electrochemical detection of trace amines in human plasma and platelets and expression of mRNA transcripts of trace amine receptors in circulating leukocytes. Neurosci Lett 2003;346(1–2):89–92.Google Scholar
  7. 7.
    Chantre P, Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine 2002:3–8.Google Scholar
  8. 8.
    Kao YH, Hiipakka RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 2000:980–987.Google Scholar
  9. 9.
    Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999:1040–1045.Google Scholar
  10. 10.
    Kaegi E. Unconventional therapies for cancer: 2. Green tea. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 1998:1033–1035.Google Scholar
  11. 11.
    Powers SH, Howley ET. Exercise Physiology: Theory and Application to Fitness and Performance. Hormonal Responses to Exercise. Boston: McGraw Hill; 2001:66–97.Google Scholar
  12. 12.
    Durand J, Giacobino JP, Girardier L. Catechol-O-methyl transferase activity in whole brown adipose tissue of rat in vitro. Experientia Suppl 1978:45–53.Google Scholar
  13. 13.
    Houston ME. Biochemistry Primer for Exercise Science. 2nd ed. Champaign, IL: Human Kinetics Publishers; 2001:113–140.Google Scholar
  14. 14.
    Butcher RW, Baird CE, Sutherland EW. Effects of lipolytic and antilipolytic substances on adenosine 3′,5′-monophosphate levels in isolated fat cells. T Biol Chem 1968:1705–1712.Google Scholar
  15. 15.
    Kalman DS, Rubin S, Martinez T, Schwartz H. Efficacy of a commercial green tea extract/caffeine based product to increase basal metabolism in healthy adults. NIH/NIDDK: The Interaction of Physical Activity and Nutrition: Biological Remodeling and Plasticity Conference, 2002.Google Scholar
  16. 16.
    Kalman DS, RS, Schwartz H. An acute clinical trial to evaluate the safety of a popular commercial weight loss supplement when used with exercise. Experimental Biology Conference, 2003, San Diego CA.Google Scholar
  17. 17.
    Wu CH, Lu FH, Chang CS, Chang TC, Wang RH, Chang CJ. Relationship among habitual tea consumption, percent body fat, and body fat distribution. Obes Res 2003:1088–1095.Google Scholar
  18. 18.
    Mitscher LA, ML, Jung M, Shankel D, et al. Chemoprotection: a review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents. Med Res Rev 1997:327–365.Google Scholar
  19. 19.
    Bushman JL. Green tea and cancer in humans: a review of the literature. Nutr Cancer 1998:151–159.Google Scholar
  20. 20.
    Siddiqui IA, Afaq F, Adhami VM, Ahmad N, Mukhtar H. Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal 2004:571–582.Google Scholar
  21. 21.
    Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother 1999:426–428.Google Scholar
  22. 22.
    Booth SL, Madabushi HT, Davidson KW, Sadowski JA. Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone). J Am Diet Assoc 1995:82–83.Google Scholar
  23. 23.
    Astrup A, Toubro S, Christensen NJ, Quaade F. Pharmacology of thermogenic drugs. Am J Clin Nutr 1992:246S–248S.Google Scholar
  24. 24.
    Bracco D, Ferrarra JM, Arnaud MJ, Jequier E, Schutz Y. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women. Am J Physiol 1995:E671–678.Google Scholar
  25. 25.
    Arciero PJ, Gardner AW, Calles-Escandon J, Benowitz NL, Poehlman ET. Effects of caffeine ingestion on NE kinetics, fat oxidation, and energy expenditure in younger and older men. Am J Physiol 1995:E1192–1198.Google Scholar
  26. 26.
    Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K, Jequier E. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am J Clin Nutr 1980:989–997.Google Scholar
  27. 27.
    Acheson KJ, Gremaud G, Meirim I, et al. Metabolic effects of caffeine in humans: lipid oxidation or futile cycling? Am J Clin Nutr 2004:40–46.Google Scholar
  28. 28.
    Bellet S, Roman L, DeCastro O, Kim KE, Kershbaum A. Effect of coffee ingestion on catecholamine release. Metabolism 1969:288–291.Google Scholar
  29. 29.
    Debrah K, Haigh R, Sherwin R, Murphy J, Kerr D. Effect of acute and chronic caffeine use on the cerebrovascular, cardiovascular and hormonal responses to orthostasis in healthy volunteers. Clin Sci (Lond) 1995:475–480.Google Scholar
  30. 30.
    Wald A, Back C, Bayless TM. Effect of caffeine on the human small intestine. Gastroenterology 1976:738–742.Google Scholar
  31. 31.
    Park Y, Albright KJ, Storkson JM, Liu W, Cook ME, Pariza MW. Changes in body composition in mice during feeding and withdrawal of conjugated linoleic acid. Lipids 1999;34:243–248.CrossRefGoogle Scholar
  32. 32.
    Terpstra AH. Effect of conjugated linoleic acid on body composition and plasma lipids in humans: an overview of the litcraturc. Am J Clin Nutr 2004:352–361.Google Scholar
  33. 33.
    Pariza MW, Ha YL. Conjugated dienoic derivatives of linoleic acid: a new class of anticarcinogens. Med Oncol Tumor Pharmacother 1990:169–171.Google Scholar
  34. 34.
    Ritzenthaler KL, McGuire MK, Falen R, Shultz TD, Dasgupta N, McGuire MA. Estimation of conjugated linoleic acid intake by written dietary assessment methodologies underestimates actual intake evaluated by food duplicate methodology. J Nutr 2001:1548–1554.Google Scholar
  35. 35.
    Terpstra AH. Effect of conjugated linoleic acid on body composition and plasma lipids in humans: an overview of the literature. Am J Clin Nutr 2004:352–361.Google Scholar
  36. 36.
    Pariza MW, Ha YL, Benjamin H, et al. Formation and action of anticarcinogenic fatty acids. Adv Exp Med Biol 1991:269–272.Google Scholar
  37. 37.
    Bontempo V, Sciannimanico D, Pastorelli G, Rossi R, Rosi F, Corino C. Dietary conjugated linoleic acid positively affects immunologic variables in lactating sows and piglets. J Nutr 2004:817–824.Google Scholar
  38. 38.
    Sebedio JL, Gnaedig S, Chardigny JM. Recent advances in conjugated linoleic acid research. Curr Opin Clin Nutr Metab Care 1999:499–506.Google Scholar
  39. 39.
    MacDonald H. Conjugated linoleic acid and disease prevention: a review of current knowledge. J Am Coll Nutr 2000:111S–118S.Google Scholar
  40. 40.
    Riserus U, Smedman A, Basu S, Vessby B. CLA and body weight regulation in humans. Lipids 2003:133–137.Google Scholar
  41. 41.
    Brown JM, McIntosh MK. Conjugated linoleic acid in humans: regulation of adiposity and insulin sensitivity. J Nutr 2003:3041–3046.Google Scholar
  42. 42.
    Malpuech-Brugere C, Verboeket-van de Venne WP, Mensink RP, et al. Effects of two conjugated linoleic acid isomers on body fat mass in overweight humans. Obes Res 2004:591–598.Google Scholar
  43. 43.
    Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans-10,cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 1999:235–241.Google Scholar
  44. 44.
    Azain MJ, Hausman DB, Sisk MB, Flatt WP, Lewell DE. Dietary conjugated linoleic acid reduces rat adipose tissue cell size rather than cell number. J Nutr 2000:1548–1554.Google Scholar
  45. 45.
    Gavino VC, Gavino G, Leblanc MJ, Tuchweber B. An isomeric mixture of conjugated linoleic acids but not pure cis-9, trans-11-octadecadienoic acid affects body weight gain and plasma lipids in hamsters. J Nutr 2000:27–29.Google Scholar
  46. 46.
    Gaullier JM, Halse J, Hoye K, et al. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr 2004;79:1118–1125.Google Scholar
  47. 47.
    Wang Y, Jones PJ. Dietary conjugated linoleic acid and body composition. Am J Clin Nutr 2004;79:1153S–1158S.Google Scholar
  48. 48.
    Mhurchu CN, Poppitt SD, McGill AT, et al. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord 2004:1149–1156.Google Scholar
  49. 49.
    Kanauchi O, Deuchi K, Imasato Y, Shizukuishi M, Kobayashi E. Mechanism for the inhibition of fat digestion by chitosan and for the synergistic effect of ascorbate. Biosci Biotechnol Biochem 1995:786–790.Google Scholar
  50. 50.
    Deuchi K, Kanauchi O, Imasato Y, Kobayashi E. Effect of the viscosity or deacetylation degree of chitosan on fecal fat excreted from rats fed on a high-fat diet. Biosci Biotechnol Biochem 1995:781–785.Google Scholar
  51. 51.
    Deuchi K, Kanauchi O, Shizukuishi M, Kobayashi E. Continuous and massive intake of chitosan affects mineral and fat-soluble vitamin status in rats fed on a high-fat diet. Biosci Biotechnol Biochem 1995:1211–1216.Google Scholar
  52. 52.
    Hellerstein MK. Is chromium supplementation effective in managing type II diabetes? Nutr Rev 1998:302–306.Google Scholar
  53. 53.
    Guthrie H, Picciano MF. Micronutrient Minerals. In: Human Nutrition. Mosby. St. Louis; 1995:333–380.Google Scholar
  54. 54.
    Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977:531–538.Google Scholar
  55. 55.
    Evans GW, Bowman TD. Chromium picolinate increases membrane fluidity and rate of insulin internalization. J Inorg Biochem 1992:243–250.Google Scholar
  56. 56.
    Vincent JB. The biochemistry of chromium. J Nutr. 2000:Apr;130(4):715–718.Google Scholar
  57. 57.
    Trent LK, Thieding-Cancel D. Effects of chromium picolinate on body composition. J Sports Med Phys Fitness 1995:273–280.Google Scholar
  58. 58.
    Volpe SL, Huang HW, Larpadisorn K, Lesser II. Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. J Am Coll Nutr 2001:293–306.Google Scholar
  59. 59.
    Clancy SP, Clarkson PM, DeCheke ME, et al. Effects of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players. Int J Sport Nutr 1994:142–153.Google Scholar
  60. 60.
    Hallmark MA, Reynolds TH, DeSouza CA, Dotson CO, Anderson RA, Rogers MA. Effects of chromium and resistive training on muscle strength and body composition. Med Sci Sports Exerc 1996:139–144.Google Scholar
  61. 61.
    Lefavi RG, Anderson RA, Keith RE, Wilson GD, McMillan JL, Stone MH. Efficacy of chromium supplementation in athletes: emphasis on anabolism. Int J Sport Nutr 1992:111–122.Google Scholar
  62. 62.
    Lukaski HC, Bolonchuk WW, Siders WA, Milne DB. Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men. Am J Clin Nutr 1996:954–965.Google Scholar
  63. 63.
  64. 64.
    Centers for Disease Control. Cigarette Smoking-Related Mortality. 2001. Available at:
  65. 65.
    Kvasz M, Allen IE, Gordon MJ, et al. Adverse drug reactions in hospitalized patients: a critique of a meta-analysis. MedGenMed 2000;2(2):E3.Google Scholar
  66. 66.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200.CrossRefGoogle Scholar
  67. 67.
    Sullum J. What’s Wrong With Mahuang? The Weak Case Against Ephedra, in Reason Online. 2003. Available at:
  68. 68.
  69. 69.
  70. 70.
    Kreider R, Shonteh H, Magu B, Rasmussen C. Effects of Coleus forskohlii supplementation on body composition and markers of health in sedentary overweight females. FASEB, New Orleans, LA 2002.Google Scholar
  71. 71.
    Baumann G, Felix S, Sattelberger U, Klein G. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy—a comparative study with dobutamine and sodium nitroprusside. J Cardiovasc Pharmacol 1990:93–100.Google Scholar
  72. 72.
    van Loon LJ, van Rooijen JJ, Niesen B, Verhagen H, Saris WH, Wageumakers AJ. Effects of acute (-)-hydroxycitrate supplementation on substrate metabolism at rest and during exercise in humans. Am J Clin Nutr 2000:1445–1450.Google Scholar
  73. 73.
    Watson JA, Fang M, Lowenstein JM. Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. Arch Biochem Biophys 1969:209–217.Google Scholar
  74. 74.
    Leonhardt M, Langhans W. Hydroxycitrate has long-term effects on feeding behavior, body weight regain and metabolism after body weight loss in male rats. J Nutr 2002:1977–1982.Google Scholar
  75. 75.
    Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003;138:468–471.Google Scholar
  76. 76.
    Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833–1838.CrossRefGoogle Scholar
  77. 77.
    Rawson ES, Clarkson PM. Ephedrine as an ergogenic aid. In: Bahrke MS, Yesalis CE, eds. Performance-Enhancing Substances in Sport and Exercise. Champaign, IL: Human Kinetics Publishers; 2002:289–298.Google Scholar
  78. 78.
    Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002;77:12–16.CrossRefGoogle Scholar
  79. 79.
    Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003;289:1537–1545.CrossRefGoogle Scholar
  80. 80.
    Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996:199–248.Google Scholar
  81. 81.
    Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992;16:269–277.Google Scholar
  82. 82.
    Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord 1993; 17(Suppl 1):S41–43.Google Scholar
  83. 83.
    Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: human studies. Int J Obes 1986;10:467–481.Google Scholar
  84. 84.
    Bell DG, Jacobs I. Combined caffeine and ephedrine ingestion improves run times of Canadian Forces Warrior Test. Aviat Space Environ Med 1999;70:325–329.Google Scholar
  85. 85.
    Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. Med Sci Sports Exerc 2001;33:1399–1403.CrossRefGoogle Scholar
  86. 86.
    Bell DG, Jacobs I, McLellan TM, Zamecnik J. Reducing the dose of combined caffeine and ephedrine preserves the ergogenic effect. Aviat Space Environ Med 2000;71:415–419.Google Scholar
  87. 87.
    Bell DG, Jacobs I, Zamecnik J. Effects of caffeine, ephedrine and their combination on time to exhaustion during high-intensity exercise [see comments]. Eur J Appl Physiol 1998;77:427–433.CrossRefGoogle Scholar
  88. 88.
    Bell DG, McLellan TM, Sabiston CM. Effect of ingesting caffeine and ephedrine on 10-km run performance. Med Sci Sports Exerc 2002;34:344–349.CrossRefGoogle Scholar
  89. 89.
    Jacobs I, Pasternak H, Bell DG. Effects of ephedrine, caffeine, and their combination on muscular endurance. Med Sci Sports Exerc 2003;35:987–994.CrossRefGoogle Scholar
  90. 90.
    Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm 2000;57:963–969.Google Scholar
  91. 91.
    Gurley BJ, Wang P, Gardner SF. Ephedrine-type alkaloid content of nutritional supplements containing Ephedra sinica (Ma-huang) as determined by high performance liquid chromatography. T Pharm Sci 1998;87:1547–1553.CrossRefGoogle Scholar
  92. 92.
    Sagara K, Oshima T, Misaki T. A simultaneous determination of norephedrine, pseudoephedrine, ephedrine and methylephedrine in Ephedrae Herba and oriental pharmaceutical preparations by ion-pair high-performance liquid chromatography. Chern Pharm Bull (Tokyo) 1983;31:2359–2365.CrossRefGoogle Scholar
  93. 93.
    Dulloo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 1993;17(Suppl 1):S35–40.Google Scholar
  94. 94.
    Dulloo AG, Seydoux J, Girardier L. Paraxanthine (metabolite of caffeine) mimics caffeine’s interaction with sympathetic control of thermogenesis. Am J Physiol 1994;267:E801–804.Google Scholar
  95. 95.
    Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001;161:1814–1824.CrossRefGoogle Scholar
  96. 96.
    Astrup A, Breum L, Toubro S, Hein P, Quaade F. Ephedrine and weight loss. Int J Obes Relat Metab Disord 1992;16:715.Google Scholar
  97. 97.
    Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002;26:593–604.CrossRefGoogle Scholar
  98. 98.
    Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon TL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord 2001;25:316–324.CrossRefGoogle Scholar
  99. 99.
    Kreider RB. Ephedra update: AMA and AHA respond. Muscular Dev 2003;40:122–127.Google Scholar
  100. 100.
    Marcus DM, Grollman AP. Ephedra-free is not danger-free. Science 2003;301:1669–1671; author reply 1669–1671.CrossRefGoogle Scholar
  101. 101.
    Penzak SR, Jann MW, Cold TA, Hon YY, Desai HD, Gurley BJ. Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol 2001;41:1059–1063.CrossRefGoogle Scholar
  102. 102.
    Nykamp DL, Fackih MN, Compton AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. Ann Pharmacother 2004;38:812–816.CrossRefGoogle Scholar

Copyright information

© Humana Press. a part of Spring Science+Business Media, LLC 2008

Authors and Affiliations

  • Christopher R. Mohr

There are no affiliations available

Personalised recommendations